# Study of IRX4204 for Treatment of Early Parkinson's Disease

> **NCT02438215** · PHASE1 · COMPLETED · sponsor: **Io Therapeutics** · enrollment: 15 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** IRX4204

## Key facts

- **NCT ID:** NCT02438215
- **Lead sponsor:** Io Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2015-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02438215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02438215, "Study of IRX4204 for Treatment of Early Parkinson's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02438215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*